Evidence review · from the 250-topic plan
The step-down lane: maintaining tirzepatide results on semaglutide prices
The idea circulating in clinics and forums: lose on tirzepatide's stronger averages, then maintain at goal on cheaper semaglutide. Here is its exact evidence status, stated the way marketing won't: no trial has tested this sequence. What trials have proven: stopping entirely fails (SURMOUNT-4, STEP-1's extension), and semaglutide maintains semaglutide-achieved loss superbly — in STEP-4, patients continuing 2.4 mg after a run-in kept losing (~8 further points over 48 weeks) while those switched to placebo regained most of their loss. The unproven link is whether sema holds a larger, tirzepatide-achieved loss. So the lane is practice-led with a half-certificate — worth a clinician conversation for the right candidate, priced at real money: against tiered maintenance rates, the step-down can cut a maintenance year from ~$3,300 to the audited $1,428.
The evidence map, drawn precisely
Three certified facts triangulate this lane. One: maintenance requires ongoing therapy — the withdrawal trials put regain at roughly half within a year off tirzepatide and about two-thirds off semaglutide. Stopping is the proven failure. Two: semaglutide is a proven maintainer of its own results — STEP-4's continuation arm didn't just hold, it extended, while its withdrawal arm regained. Three: tirzepatide out-loses semaglutide head-to-head (~20.2 vs ~13.7 in SURMOUNT-5). The lane splices facts two and three — descend on the stronger drug, hold on the proven maintainer — and the splice itself is the untested part. Precision about that seam is what separates this article from a sales page.
Why clinicians find it plausible
Maintenance and loss are different metabolic jobs: holding a weight doesn't require the deficit that reaching it did, and appetite regulation — the class's core mechanism — is the maintenance-relevant lever both molecules pull. Semaglutide at 2.4 mg demonstrably suppresses the regain biology in its own patients; the working hypothesis is that the same suppression generalizes to a lower starting weight regardless of which molecule built it. Reasonable, mechanistic — and a hypothesis, which is the word this paragraph exists to keep attached.
What's genuinely unknown
Three open questions your clinician can't answer from trials, only manage in practice: whether a tirzepatide-sized loss (often 20%+) generates stronger regain pressure than sema's ceiling can hold; whether the switch transition itself — new receptor profile, mid-ladder entry — costs a regain window; and who the responders are, since individual variation dwarfs averages in both directions. The honest protocol treats the step-down as an experiment with an exit: defined weigh-in cadence, a pre-agreed regain threshold (clinics often use a few percent), and a documented plan to step back up if the hold slips. An experiment with instrumentation is medicine; one without is hope.
The money case, run honestly
Against the audited flats, the step-down saves a modest $240/year ($1,668 → $1,428) — real, not dramatic. The dramatic version lives in the tiered market, where maintenance is exactly where dose-tier pricing peaks: a patient holding at a $299-tier rate pays ~$3,588/year to maintain, and the step-down to the $119 floor cuts that by over $2,100 — the single largest legitimate saving this site has priced that doesn't involve insurance. Which reframes the decision cleanly: on flat pricing, step down only if the medicine argues for it; on tier pricing, the step-down is also an escape from the architecture. The $1,428 maintenance year ↗
Candidacy and the clinician conversation
The profile that fits: at or near goal, stable for a couple of cycles, motivated by cost or tolerability, no history of sema intolerance, and willing to run the instrumented experiment above. The profile that doesn't: mid-descent (you'd be trading engines uphill), history of strong regain pressure, or anyone whose plan is really “step down, then quietly off” — the withdrawal data has already graded that essay. Bring to the appointment: your loss history by molecule and dose, the STEP-4 fact pattern, and the three unknowns — a clinician hearing those from a patient knows the conversation can be a real one.
FAQ
Can you maintain tirzepatide weight loss with semaglutide?
No trial has tested the sequence. Proven: semaglutide maintains semaglutide-achieved loss (STEP-4), and stopping entirely leads to major regain. The tirz-to-sema hold is plausible, practice-led, and best run as a monitored experiment with a step-back plan.
How much does stepping down save?
$240/year between the audited flats — but over $2,100/year for patients escaping $299-class tiered maintenance to the $119 floor.
Who is a good candidate for the step-down lane?
Patients at goal and stable for multiple cycles, cost- or tolerability-motivated, sema-tolerant, with a defined monitoring plan and regain threshold agreed with their clinician.
What did STEP-4 actually show?
After a semaglutide run-in, patients continuing 2.4 mg lost roughly eight further points over 48 weeks while those switched to placebo regained most of their loss — the maintenance certificate, on semaglutide's own results.
Sources
- STEP-4 (semaglutide maintenance/withdrawal), NEJM/JAMA program publications.
- SURMOUNT-4 and STEP-1 extension — the stopping data; SURMOUNT-5 — the head-to-head.
- Audited flat pricing and on-record tier maintenance rates — the open dataset.